News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Reports Positive Results From First Phase 3 Trial With N8-GP, A Long-Acting Factor VIII For Treatment Of Haemophilia A



3/19/2014 9:49:45 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Bagsvaerd, Denmark, March 19, 2014 (GLOBE NEWSWIRE) -- Novo Nordisk today announced the completion of pathfinder(TM)2, the first phase 3 trial with long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol) for haemophilia A patients. Pathfinder(TM)2 is a multi-national trial evaluating safety and efficacy of N8-GP, when administered for prophylaxis and on-demand treatment in patients with haemophilia A, who are 12 years or older.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES